Barclays Lowers Clorox (NYSE:CLX) Price Target to $112.00

Clorox (NYSE:CLX) had its price objective cut by investment analysts at Barclays from $118.00 to $112.00 in a report issued on Tuesday, Marketbeat reports. The firm presently has an “underweight” rating on the stock. Barclays‘s target price suggests a potential downside of 8.67% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. lifted their price target on shares of Clorox from $133.00 to $135.00 and gave the stock a “neutral” rating in a research note on Monday, September 8th. Jefferies Financial Group decreased their price objective on shares of Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Wells Fargo & Company decreased their price objective on shares of Clorox from $130.00 to $125.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 25th. Morgan Stanley decreased their price objective on shares of Clorox from $150.00 to $137.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Finally, Citigroup restated a “neutral” rating and set a $135.00 price objective (down from $140.00) on shares of Clorox in a research report on Tuesday, July 15th. One research analyst has rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $134.08.

Clorox Trading Down 0.5%

Shares of CLX stock opened at $122.64 on Tuesday. The firm’s 50 day moving average is $123.15 and its 200 day moving average is $129.96. The stock has a market capitalization of $15.00 billion, a P/E ratio of 18.81, a P/E/G ratio of 0.99 and a beta of 0.52. Clorox has a 12-month low of $116.53 and a 12-month high of $171.37. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.63. The business had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.82 EPS. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Research analysts expect that Clorox will post 7.15 earnings per share for the current year.

Insider Transactions at Clorox

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.57% of the company’s stock.

Institutional Trading of Clorox

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sonora Investment Management Group LLC grew its stake in shares of Clorox by 2.5% in the 1st quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company’s stock worth $433,000 after buying an additional 72 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Clorox by 0.6% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company’s stock worth $1,953,000 after buying an additional 73 shares in the last quarter. Horizon Investments LLC grew its stake in shares of Clorox by 4.4% in the 1st quarter. Horizon Investments LLC now owns 1,768 shares of the company’s stock worth $258,000 after buying an additional 75 shares in the last quarter. Sfmg LLC grew its stake in shares of Clorox by 2.8% in the 1st quarter. Sfmg LLC now owns 2,780 shares of the company’s stock worth $409,000 after buying an additional 76 shares in the last quarter. Finally, Hancock Whitney Corp grew its stake in shares of Clorox by 4.3% in the 1st quarter. Hancock Whitney Corp now owns 2,064 shares of the company’s stock worth $304,000 after buying an additional 86 shares in the last quarter. 78.53% of the stock is currently owned by institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.